A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND 74019, NSC 736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma.

Trial Profile

A Phase II Evaluation of SU11248 (Sunitinib Malate) (IND 74019, NSC 736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Sep 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top